AT1 · ASX

Atomo Diagnostics Ltd. (ASX:AT1)

AU$0.021

 -0.001 (-4.545%)
ASX:Live
01/11/2024 04:10:21 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

AT1 Overview

AT1 Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About AT1

Telephone

Address

Description

Atomo Diagnostics Ltd. engages in manufacture, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. It offers its products through the AtomoRapid range of RDT platforms. The company was founded by John Kelly in 2010 and is headquartered in Leichhardt, Australia.

AT1 Price Chart

Key Stats

Market Cap

AU$14.06M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.06

Trade Value (12mth)

AU$4,903.00

1 week

0%

1 month

4.76%

YTD

-8.33%

1 year

0%

All time high

0.63

Key Fundamentals

EPS 3 yr Growth

0.90%

EBITDA Margin

-134.60%

Operating Cashflow

-$5m

Free Cash Flow Return

-37.60%

ROIC

-54.90%

Interest Coverage

-577.90

Quick Ratio

4.80

Other Data

Shares on Issue (Fully Dilluted)

639m

HALO Sector

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

AT1 Announcements

Latest Announcements

Date Announcements

29 October 24

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

24 October 24

Atomo Investor Webinar Presentation

×

Atomo Investor Webinar Presentation

23 October 24

Atomo Secures $2.44m Grant to Develop Syphilis Test

×

Atomo Secures $2.44m Grant to Develop Syphilis Test

15 October 24

2024 Notice of Annual General Meeting

×

2024 Notice of Annual General Meeting

29 August 24

2024 Appendix 4E and Annual Report

×

2024 Appendix 4E and Annual Report

29 August 24

FY24 Results Presentation

×

FY24 Results Presentation

29 August 24

2024 Appendix 4G and Corporate Governance Statement

×

2024 Appendix 4G and Corporate Governance Statement

29 August 24

Atomo Investor Webinar Presentation

×

Atomo Investor Webinar Presentation

25 July 24

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

22 July 24

Atomo Investor Webinar Presentation

×

Atomo Investor Webinar Presentation

09 July 24

Notification of cessation of securities - AT1

×

Notification of cessation of securities - AT1

09 July 24

Change of Director's Interest Notice - John Kelly

×

Change of Director's Interest Notice - John Kelly

12 June 24

Government funded procurement of Atomo HIV tests commencing

×

Government funded procurement of Atomo HIV tests commencing

11 June 24

Change of Company Secretary

×

Change of Company Secretary

16 May 24

Significant funding to HIV Self-Testing in Federal Budget

×

Significant funding to HIV Self-Testing in Federal Budget

30 April 24

Notification of cessation of securities - AT1

×

Notification of cessation of securities - AT1

29 April 24

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

24 April 24

Atomo Investor Webinar Presentation

×

Atomo Investor Webinar Presentation

15 April 24

AT1 secures significant order for HIV self-tests

×

AT1 secures significant order for HIV self-tests

06 March 24

AT1 secures significant order for HIV self tests for LMIC

×

AT1 secures significant order for HIV self tests for LMIC

04 March 24

Change of Company Secretary

×

Change of Company Secretary

26 February 24

Appendix 4D and Half Year Report ended 31 Dec 2023

×

Appendix 4D and Half Year Report ended 31 Dec 2023

26 February 24

H1 FY24 Results Presentation

×

H1 FY24 Results Presentation

21 February 24

Investor Webinar Presentation

×

Investor Webinar Presentation

29 January 24

Appendix 4C - 31 December 2023

×

Appendix 4C - 31 December 2023

AT1 Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.02 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.02 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 6.5 -74.0 37.9 Lock Lock Lock
     PE X Lock Lock Lock Lock 65.0 N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 32.0 N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 17.4 -132.4 51.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -13.2 -47.0 -29.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.0 N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.04 0.03 0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.04 0.02 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.9 -45.9 -37.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 569 571 635 Lock Lock Lock
Basic m Lock Lock Lock Lock 569 571 635 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 12 3 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 83.7 -79.4 60.7 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 6 4 3 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -6 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.3 -227.8 32.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -15.0 -238.9 -100.1 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 115 339 200 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -8 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -25.7 -33.4 32.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -49.5 -320.3 -134.6 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -8 -10 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.2 -23.8 28.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -65.7 -394.7 -175.2 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -11 -8 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -10 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 5.2 -74.5 31.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -46.3 -391.5 -167.6 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -6 -5 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 2 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -2 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 0 2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 -6 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 42.8 -40.7 20.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.3 -2.3 -1.2 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 13 6 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 27 16 11 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -13 -6 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 25 15 10 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 25 15 10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -16.9 -40.5 -32.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.4 -60.4 -60.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -23.0 -67.3 -67.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -29.3 -49.9 -56.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -20.7 -49.9 -54.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -10.2 -29.3 -37.6 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -394.9 -543.6 -577.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.1 0.8 0.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -50.9 -42.0 -35.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 12.5 7.0 6.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 10.2 5.5 4.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 68.0 62.0 48.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -183.4 -391.3 -394.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 3.4 1.1 2.1 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 4.4 3.1 4.1 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.7 0.3 0.6 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 3.1 7.1 11.7 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.5 0.2 0.4 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.5 0.2 0.4 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -54.6 -428.7 -190.6 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -25.3 -66.2 -68.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.4 -60.4 -60.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -23.0 -67.3 -67.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -23.0 -67.3 -67.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 83.1 117.6 88.7 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 106.1 323.0 173.6 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 189.2 440.6 262.3 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 12.9 13.9 15.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 176.3 426.8 247.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

AT1 Shortsell

Frequently Asked Questions

The current share price of Atomo Diagnostics Ltd. (AT1:ASX) is AU$0.021.
The 52-week high share price for Atomo Diagnostics Ltd. (AT1:ASX) is AU$0.06.
The 52-week low share price for Atomo Diagnostics Ltd. (AT1:ASX)? is AU$0.02.
Atomo Diagnostics Ltd. (AT1:ASX) does not pay a dividend.
Atomo Diagnostics Ltd. (AT1:ASX) does not pay a dividend.
Atomo Diagnostics Ltd. (AT1:ASX) has a franking level of 0.0%.
Atomo Diagnostics Ltd. (AT1:ASX) is classified in the Healthcare.
The current P/E ratio for Atomo Diagnostics Ltd. (AT1:ASX) is .